News | March 25, 2009

Lantheus to Present New Cardiac Imaging Data at ACC

March 25, 2009 – Lantheus Medical Imaging Inc. today announced that new data for the company’s echocardiography contrast agent DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension and its novel fluorine 18-labeled Positron Emission Tomography (PET) agent for myocardial perfusion imaging, BMS747158, will be presented in two separate poster presentations at the American College of Cardiology 58th Annual Scientific Session on March 29-31, 2009, in Orlando, Florida.

New data on survival in an intensive care unit population undergoing transthoracic echocardiography with and without perflutren containing ultrasound contrast agents will be presented. The retrospective study includes more than 39,000 propensity-matched cases in patients undergoing transthoracic echocardiography with and without contrast agents. The majority of the perflutren cases used DEFINITY, which is the market-leading product in ultrasound echocardiography contrast agents in the U.S. Additionally, Phase I data regarding the human safety, dosimetry, biodistribution, and myocardial perfusion imaging characteristics under rest and stress conditions of Lantheus’ new PET agent BMS747158 will be presented.

“The new DEFINITY data expand on findings published in December 2008 that showed that the use of DEFINITY for enhancing suboptimal resting echocardiography exams was associated with a 26 percent lower risk of mortality when compared with echocardiography performed without a contrast agent. Additionally, the PET agent data further demonstrate Lantheus’ ongoing commitment to developing new agents for the diagnosis and management of cardiovascular disease,” said Don Kiepert, president and CEO, Lantheus Medical Imaging, Inc.

The abstract “Survival in an Intensive Care Unit Population Undergoing Transthoracic Echocardiography With and Without Perflutren Containing Ultrasound Contrast Agents: Results in 39,189 Propensity Matched Cases” will be presented on Sunday, March 29, 2009, 3:30 p.m. - 4:30 p.m. The presenter is Michael L. Main M.D., associate professor of medicine, University of Missouri-Kansas City and director, echocardiography laboratory, Saint Luke’s Mid America Heart Institute, Kansas City, MI.

The second abstract, “Phase 1 Human Safety, Dosimetry, Biodistribution, and Rest/Stress Myocardial Imaging Characteristics of F-18 Labeled BMS747158,” will be presented on Tuesday, March 31, 2009, 9:30 a.m. - 10:30 a.m., by Jamshid Maddahi, M.D., F.A.C.C., professor of molecular and medical pharmacology (nuclear medicine) and medicine (cardiology) at David Geffen School of Medicine at UCLA.

For more information: www.lantheus.com

Related Content

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
Trends in contrast media used in magnetic resonance imaging and computed tomography

Image courtesy of Bayer

Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast...
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly...
Overlay Init